Yimeng Du

Yimeng Du

Auto-generated profile, based on publicly available information

Yimeng Du

Department of Cardiology The Second Hospital of Shandong University Jinan China

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 August 2019 in IEEE Transactions on Magnetics
Verified
Journal Article
Closed access
XLXuyang Liu
Xuyang Liu
KLKing Hang LAM
King Hang LAM
KZKe Zhu
Ke Zhu
CZChao Zheng
Chao Zheng
XLX. Li
X. Li
Philip PongPhilip Pong
Philip Pong
Smart living is a trending and connected lifestyle that envisions efficient and sustainable energy utilization, stable and reliable power supply, intelligent and coordinated transportation and mobility, and personalized and cost-effective healthcare. Its realization needs the Internet of Things (IoT). IoT is a compelling platform connecting trillions of sensors and collecting data for connectivity and analytics. It is more advanced than traditional monitoring systems where limited sensors and wired communication can merely collect fragmented data in the application domains. Spintronic sensors with the superb measuring ability and multiple unique advantages can be one of the critical sensing devices supporting the IoT and enabling smart living. In this paper, we review successful applications of individual spintronic sensors in electrical current sensing, transmission and distribution lines monitoring, vehicle detection, and biodetection that can help to fulfill the promises of smart living in energy management, power delivery, transport, and healthcare. The wireless spintronic sensor networks (WSSNs) working at the massive interconnected network level are proposed and illustrated to provide pervasive monitoring systems, which facilitate the intelligent surveillance and management over building, power grid, transport, and healthcare. The database of collected information will be of great use to policy making in public services and city planning. This paper provides insights for realizing smart living through the integration of IoT with spintronic sensor technology.

19 January 2011 in Lipids in Health and Disease
Verified
Journal Article
Open access
PDF file
HGHui-Ping Gong
Hui-Ping Gong
YDYi-Meng Du
Yi-Meng Du
LZLi-Na Zhong
Li-Na Zhong
ZDZhao-Qiang Dong
Zhao-Qiang Dong
XWXin Wang
Xin Wang
QLQing-Hua Lu
Qing-Hua Lu
Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a recently identified and potentially useful plasma biomarker for cardiovascular and atherosclerotic diseases. However, the correlation between the Lp-PLA2 activity and carotid atherosclerosis remains poorly investigated in patients with metabolic syndrome (MetS). The present study aimed to evaluate the potential role of Lp-PLA2 as a comprehensive marker of metabolic syndrome in individuals with and without carotid atherosclerosis. We documented 118 consecutive patients with MetS and 70 age- and sex-matched healthy subjects served as controls. The patients were further divided into two groups: 39 with carotid plaques and 79 without carotid plaques to elucidate the influence of Lp-PLA2 on carotid atherosclerosis. The plasma Lp-PLA2 activity was measured by using ELISA method and carotid intimal-media thickness (IMT) was performed by ultrasound in all participants. Lp-PLA2 activity was significantly increased in MetS subgroups when compared with controls, and was higher in patients with carotid plaques than those without plaques (P < 0.05). Furthermore, we found that significant difference in Lp-PLA2 was obtained between patients with three and four disorders of metabolic syndrome (P < 0.01). Age (β = 0.183, P = 0.029), LDL-cholesterol (β = 0.401, P = 0.000) and waist-hip ratio (β = 0.410, P = 0.000) emerged as significant and independent determinants of Lp-PLA2 activity. Multiple stepwise regression analysis revealed that LDL-cholesterol (β = 0.309, P = 0.000), systolic blood pressure (β = 0.322, P = 0.002) and age (β = 0.235, P = 0.007) significantly correlated with max IMT, and Lp-PLA2 was not an independent predictor for carotid IMT. Lp-PLA2 may be a modulating factor for carotid IMT via age and LDL-cholesterol, not independent predictor in the pathophysiological process of carotid atherosclerosis in patients with MetS.

29 May 2012 in BMC Cardiovascular Disorders
Verified
Journal Article
Open access
PDF file
WMWei-Hong Ma
Wei-Hong Ma
XWXiu-Ling Wang
Xiu-Ling Wang
YDYi-Meng Du
Yi-Meng Du
YWYi-Biao Wang
Yi-Biao Wang
YZYan Zhang
Yan Zhang
PBPei-Li Bu
Pei-Li Bu
Background: YKL-40, a proposed marker of inflammation and endothelial dysfunction, is associated with atherosclerosis and an increased cardiovascular mortality in the general population. However, the relationship between YKL-40 and arterial stiffness in hypertensive patients has not been adequately assessed. Methods: The relationship between serum levels of YKL-40 and arterial stiffness was evaluated in 93 essential hypertensive subjects and 80 normal subjects. Essential hypertensive subjects were divided into two groups based upon urinary albumin-to-creatinine ratio (ACR): nonmicroalbuminuric group, (ACR <30 mg/g, n = 50) and microalbuminuric group (ACR ≥30 mg/g, n = 43). Large artery wall stiffness was assessed by measuring femoral arterial stiffness and carotid-femoral pulse wave velocity (cf-PWV). Serum levels of YKL-40 were determined by enzyme-linked immunosorbent assay (ELISA). Results: The study demonstrated that YKL-40,cf-PWV and femoral arterial stiffness were increased significantly (P<0.05) in the hypertensive group compared with normal controls. These measurements were also increased significantly ( P<0.05) in the microalbuminuric group compared with the nonmicroalbuminuric group. YKL-40 was positively correlated with cf-PWV( r = 0.44, P = 0.000) and femoral arterial stiffness ( r = 0.42, P =0.001). Multiple linear stepwise regression analysis showed that YKL-40 was the impact factor of arterial stiffness ( P<0.05). Conclusion: YKL-40 levels are elevated in essential hypertension subjects with an independent association between increasing YKL-40 levels and increasing arterial stiffness. The study suggests it played a positive role of YKL-40 in the progressing vascular complications in patients with essential hypertension.

19 July 2017 in Experimental and Therapeutic Medicine
Verified
Journal Article
Open access
PDF file
WWWen-Ke Wang
Wen-Ke Wang
QLQing-Hua Lu
Qing-Hua Lu
XWXin Wang
Xin Wang
BWBen Wang
Ben Wang
JWJuan Wang
Juan Wang
YDYi-Meng Du
Yi-Meng Du
Ulinastatin exhibits anti-inflammatory activity and protects the heart from ischemia/reperfusion injury. However, whether ulinastatin has a protective effect in diabetic cardiomyopathy is yet to be elucidated. The aim of the present study was to investigate the protective effects of ulinastatin against diabetic cardiomyopathy and its underlying mechanisms. A C57/BL6J mice model of diabetic cardiomyopathy was used and mice were randomly assigned to three groups: Control group, diabetes mellitus (DM) group and DM + ulinastatin treatment group. Cardiac function was assessed using echocardiography and the level of inflammatory cytokine high mobility group box 1 (HMGB1) expression was measured using histopathological examination and reverse transcription‑quantitative polymerase chain reaction. The levels of tumor necrosis factor (TNF)‑α and interleukin (IL)‑6 were measured using western blotting and ELISA. The apoptosis rate in the myocardium was assessed by TUNEL assay. Caspase‑3 activation, expression of B‑cell lymphoma 2 (Bcl‑2) and Bcl‑2 associated x (Bax) were measured using western blotting, as was the activity of the mitogen activated protein kinase (MAPK) signaling pathway. The results indicated that ulinastatin significantly improved cardiac function in mice with DM. Ulinastatin treatment significantly downregulated HMGB1, TNF‑α and IL‑6 expression (P<0.05) and significantly reduced the percentage of apoptotic cardiomyocytes (P<0.05) via reduction of caspase‑3 activation and the ratio of Bax/Bcl‑2 in diabetic hearts (P<0.05). In addition, ulinastatin attenuated the activation of the MAPK signaling pathway. In conclusion, ulinastatin had a protective effect against DM‑induced cardiac dysfunction in a mouse model. This protective effect may be associated with the anti‑inflammatory and anti‑apoptotic abilities of ulinastatin via the MAPK signaling pathway.

6 July 2022 in Journal of Clinical Laboratory Analysis
Verified
Journal Article
Open access
HGHuiping Gong
Huiping Gong
JLJing Liu
Jing Liu
ZXZhiwei Xue
Zhiwei Xue
WWWenwen Wang
Wenwen Wang
CLCuicui Li
Cuicui Li
XLXiaona Lyu
Xiaona Lyu
Background: This study aimed to explore the relationship between the Sirtuin 3 (SIRT3) gene and endothelial cell dysfunction, contributing to the progression of coronary atherosclerosis driven by hyperglycemia.Methods: We measured serum SIRT3 levels using enzyme‐linked immunosorbent assay in 95 patients with type 2 diabetes mellitus (T2DM) who underwent diagnostic coronary angiography. The patients were divided into two groups according to the presence (n = 45) or absence (n = 50) of coronary artery disease (CAD). Human aortic endothelial cells (HAECs) grown in vitro in a medium with various concentrations of glucose (5.5, 11, 16.5, 22, 27.5, 33, and 38.5 mM) for 24 h were assessed for protein expression of SIRT3, peroxisome proliferator‐activated receptor alpha (PPAR‐α), endothelial nitric oxide (NO) synthase (eNOS), and inducible NO synthase (iNOS) using Western blot analysis. HAECs were subjected to SIRT3 overexpression or inhibition through SIRT3 adenovirus and siRNA transfection.Results: Serum SIRT3 levels were significantly lower in T2DM patients with CAD than in those without CAD (p = 0.048). The in vitro results showed that HG significantly increased SIRT3, PPAR‐α, and eNOS protein expression in a concentration‐dependent manner. Moreover, iNOS expression was decreased in HAECs in response to HG. Reduced PPAR‐α and eNOS levels and increased iNOS levels were observed in SIRT3 silenced HAECs cells. In contrast, SIRT3 overexpression significantly improved PPAR‐α and eNOS expression and suppressed iNOS expression.Conclusion: SIRT3 was associated with the progression of atherosclerosis in T2DM patients through upregulation of PPAR‐α and eNOS and downregulation of iNOS, which are involved in endothelial dysfunction under hyperglycemic conditions.

29 April 2020 in Drug Development and Industrial Pharmacy
Verified
Journal Article
Closed access
YXYunjie Xia
Yunjie Xia
LLLong LI
Long LI
XHXiaowu Huang
Xiaowu Huang
ZWZengming Wang
Zengming Wang
HZHui Zhang
Hui Zhang
AZAIPING ZHENG
AIPING ZHENG
The purpose of this study was to investigate the nasal absorption rate and nasal mucosal toxicity of thermosensitive ketamine in situ gels containing various absorption enhancers. The optimal composition ratio for the gel matrix was determined to be 17.2% Poloxamer 407 and 2% Poloxamer 188, as this combination resulted in solutions with a gelation point within the range found in the nasal cavity. Ketamine gels containing the tested enhancers, namely ethylenediaminetetraacetic acid disodium salt, hydroxypropyl-β-cyclodextrin, propylene glycol, or Tween-80, were compared with enhancer-free counterparts to determine the absorption of the drug, in vivo by measuring its plasma levels in rats and in vitro using a Franz diffusion cell. Moreover, the toxicity of each gel type was assessed by microscopic observation of the morphology of rat nasal mucosa as well as by determining the mobility of the mucosal cilia using an established toad model. The results showed that gels containing hydroxypropyl-β-cyclodextrin could promote the absorption of ketamine without added toxicity compared to enhancer-free gels. Thus, we consider hydroxypropyl-β-cyclodextrin as the most promising absorption enhancer for the nasal administration of ketamine using in situ gels.